Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has completed enrollment in the Motiva US IDE clinical study. The final surgery in the primary reconstruction cohort was completed at Northwestern Memorial Hospital. The Augmentation cohort, which finished enrollment in August of 2019, will complete

Establishment Labs Announces Complete Enrollment in Motiva US IDE Study

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2022 after the market closes on Monday, August 8, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U

Establishment Labs to Announce Second Quarter 2022 Financial Results on August 8

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced publication of its 2021 Sustainability Review to coincide with the fourth anniversary of the company's public listing on NASDAQ. “Our company was founded to transform the legacy of an industry through a unique commitment to women's health and wellbeing.

Establishment Labs Releases 2021 Sustainability Review

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 am Eastern Time. A live webcast of the presentation will

Establishment Labs to Present at the Jefferies Healthcare Conference

Establishment Labs Holdings, Inc. (NASDAQ:ESTA ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Juan Jose Chacon Quiros - Founder, Chief Executive Officer & Executive Director Rajbir Denhoy - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Philip Coover - Goldman Sachs Marie Thibault - BTIG Chris Cooley - Stephens Zach Weiner - Jefferies Operator Good afternoon. Welcome to Establishment Labs First Quarter 2022 Earnings Call.

Establishment Labs Holdings, Inc. (ESTA) CEO Juan Jose Chacon Quiros on Q1 2022 Results - Earnings Call Transcript

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the first quarter ended March 31, 2022. First Quarter Highlights and Outlook Strong momentum with first quarter worldwide sales of $38.5 million, an increase of 26.8% year-over-year and a new quarterly record. Gross profit for

Establishment Labs Reports Record First Quarter 2022 Financial Results

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2022 after the market closes on Monday, May 9, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S

Establishment Labs to Announce First Quarter 2022 Financial Results on May 9

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has entered into a $225 million term loan financing facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). “After a competitive process, we could not be more pleased to enter into this long-term strategic partnership with Oaktree,” said Raj Denho

Establishment Labs Enters Into $225 Million Credit Facility With Oaktree

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today noted the presentation of interim study data from the augmentation cohort of its Motiva US IDE Study. This Study Update includes two-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investi

Establishment Labs Notes Presentation of 2-Year Results from Motiva US IDE Study at The Aesthetic Meeting 2022

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its participation in The Aesthetic Meeting 2022, which is being held April 20-24 in San Diego, California, as well as sessions of interest at the meeting. Dr. Caroline Glicksman, the Medical Director for and a Principal Investigator in the Motiva US IDE Study, will present an

Establishment Labs Announces Participation in The Aesthetic Meeting 2022 and Sessions of Interest

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present virtually at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 pm Eastern Time. A live webcast of the pr

Establishment Labs to Present at the Cowen 42nd Annual Health Care Conference

Establishment Labs Holdings, Inc. (ESTA) CEO Juan Jose Chacon Quiros on Q4 2021 Results - Earnings Call Transcript

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided initial 2022 guidance. Fourth Quarter Highlights and Outlook Fourth quarter worldwide sales of $35.3 million, an increase of 31.0% year-over-year and a new q

Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results; Record Fourth Quarter Revenue of $35.3 Million

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed two million Motiva Implants® in market. “Our journey to transform breast aesthetics and reconstruction has always been guided by putting women at the center of all of our efforts and by making innovation, science, and research the foundation of all o

Establishment Labs Reaches Two Million Motiva Implants Milestone

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2021 before the market opens on Tuesday, March 1, 2022, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-803

Establishment Labs to Announce Fourth Quarter 2021 Financial Results on March 1

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today reported preliminary unaudited revenue for the three months and fiscal year ended December 31, 2021. Establishment Labs' unaudited preliminary revenue for the fourth quarter of 2021 is expected to be in the range of $35.0 million to $35.5 million, an increase of

Establishment Labs Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30pm Eastern Time. A live webcast of the presentation will be available on the Establi

Establishment Labs to Present at the 40th Annual J.P. Morgan Healthcare Conference

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August. “Raj has quickly become a trusted and vital colleague to

Establishment Labs Announces Appointment of Raj Denhoy as Chief Financial Officer

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Leslie Gillin to its Board of Directors, effective immediately. “We are very pleased to welcome Leslie to the Board of Establishment Labs,” said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. “She is extraordinarily a

Establishment Labs Announces Appointment of Leslie Gillin to Board of Directors

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Interim Chief Financial Officer and Head of Strategy and Investor Relations, will participate in the Stephens Annual Investment Conference, which is being held December 1

Establishment Labs Announces Participation in the Stephens Annual Investment Conference

Establishment Labs Holdings' (ESTA) CEO Juan José Chacón Quirós on Q3 2021 Results - Earnings Call Transcript

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the third quarter ended September 30, 2021 and provided updated 2021 guidance. Third Quarter Highlights and Outlook Third quarter worldwide sales of $29.0 million, an increase of 27.6% year-over-year. 2021 guidance increased to

Establishment Labs Reports Third Quarter 2021 Financial Results and Raises Full Year Guidance

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeffrey Bettinger has been appointed Global Head of People. Mr. Bettinger will join the executive team at Establishment Labs with responsibility for culture, employee experience, and human capital strategy. Mr. Bettinger joins Establishment Labs fr

Establishment Labs Announces Jeffrey Bettinger Has Joined the Company as Global Head of People

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2021, before the market opens on Tuesday, November 9, 2021, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 40

Establishment Labs to Announce Third Quarter 2021 Financial Results on November 9

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of JOY™, a new patient-centric breast aesthetics program. Women who select JOY will receive Establishment Labs' newest generation Motiva Ergonomix2® implants through a network of highly trained plastic surgeons as well as the most comprehensi

News for Establishment Labs Holdings Inc Stock (ESTA)